


# Identification of ALIX-V Domain Ligands of Interest as Broad-Spectrum Antivirals using phage display

M. J. Resina<sup>a</sup>, Javier Murciano<sup>a</sup>, Antonio Pozo<sup>a</sup>, Marisa Parra<sup>a</sup>, Fernando Montero<sup>a</sup>, Lucía Giraldo<sup>a</sup>, José C. Martínez<sup>a</sup>, Javier Ruiz<sup>a</sup>, Irene Luque<sup>a</sup>


<sup>a</sup> Department of Physical Chemistry, Institute of Biotechnology and Excellence Unit in Chemistry Applied to Biomedicine and Environment, School of Sciences, University of Granada, Campus Fuentenueva s/n 18071, Granada, Spain

**ABSTRACT.-** Recognition of the LYPX(n)L viral late domains by the V domain of programmed death interacting protein 6 (AIP6) or ALIX, is essential for the budding of many enveloped viruses, such as HIV, Ebola and EIAV. Blocking these interactions is a promising strategy for developing broad-spectrum antivirals. In this work, we tackle the study of the binding preferences of ALIX-V and the identification of high-affinity peptide sequences through the design and screening of randomized peptide libraries by phage display. Our results reveal a strong preference for n = 3 in high affinity ligands of the YPX(n)L type for ALIX-V. The binding of selected high-affinity sequences has been validated by MicroScale Thermophoresis, showing that the selected peptides exhibit competitive binding with natural ligands and providing valuable key elements for the search and determination of a high-affinity binding.


## 1.- The importance of the search for high-affinity peptide ligands of the human protein ALIX-V




## 2.- Experimental protocol of phage display in search for peptide ligands



## 3.- Phage display reveals a clear preference for n=3 in YPX<sub>(n)</sub>L ALIX-V ligands



## 4.- MST experiments confirm binding and establish similar dissociation constants for the natural cellular and viral peptide ligands and peptides selected by phage display



**Conclusion:** Phage display is a highly potent methodology to optimize small peptide-protein interactions. In this research, we identified three peptides with specific binding capacity to ALIX-V, which represents an advance in the search for new broad-spectrum antivirals that allow the interruption of viral budding and the proliferation of retroviruses.